Ginsenoside Rg5

Research use only, not for human use.

Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease.

Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.

——

——

——

Others

Other Targets

IGF-1R

Neurological Disease

——

186763-78-0

767.01

C42H70O12

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (65.19 mM)

CC(=CCC=C(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)C

——

(-20℃)

With Ice Pack

≥ 2 years